Non-alcoholic liver disease: study shows that PHGG inhibits the development of NAFLD
Non-alcoholic fatty liver disease (NAFLD) is one of the most widespread liver diseases worldwide. The highest rates are currently reported from South America and the Middle East followed by Asia, the US and Europe. The global prevalence of NAFLD is currently estimated at about 24% and both adults and children are affected. Also, NAFLD increases the risk for complication such as cirrhosis, liver failure or even cardiovascular diseases.